John Cullity

After earning his medical degree (MBBS) from the University of Western Australia, Dr John Cullity undertook advanced training in haematology-oncology at QEII Medical Center. He then moved to the United Kingdom to complete Royal College of Physicians examinations. He also completed a Master of Science at the London School of Economics and an MBA at The Wharton School, University of Pennsylvania. After a period consulting to World Health Organisation and The World Bank, Dr Cullity worked as a director of Health Economics (Oncology) & Strategic Pricing at Schering-Plough, and then for seven years at Sanofi-Aventis as director of Health Economics (Oncology), senior director and head of strategic pricing, and senior director of business development & licensing (Oncology). Between 2010 and 2017 in New York, Dr Cullity was a principal for Torreya Partners, the internationally-recognised transactions firm where he managed numerous licensing/M&A transactions and participated in the establishment of several biotech companies. He remains a director of Theraly Fibrosis (spin-out from Johns Hopkins University), Haemalogix (Australian immune-oncology company) and Ceramedix Holdings (spin-out from Memorial Sloan Kettering Cancer Center).
Bio last updated 07 Apr 2018

Article Timeline

Access to our data for John Cullity is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

John Cullity is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/12/18

1 year TSR5 year TSR
276thOrion Equities-3%-9%
654thDotz Nano-56%-66%
817thRace Oncology-83%
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Non-Executive Director
Year started and most recent title


194th-Race Oncology$170k
198th↓Dotz Nano$138k
199th↓Orion Equities$132k
237 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer